U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 200 points on Thursday.Following the market opening Thursday, the Dow traded down 0.56% to 49,225.33 while the NASDAQ dipped 0.89% to 22,700.74. The S&P 500 also fell, dropping, 0.74% to 6,831.80.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsConsumer staples shares gained by 0.3% on Thursday.In trading on Thursday, consumer discretionary stocks fell by 2.2%.To ...

Market Overview - U.S. stocks showed mixed performance, with the Nasdaq Composite falling over 400 points, while the Dow increased by 0.24% to 49,358.09 and the S&P 500 decreased by 0.89% to 6,856.40 [1] - Energy shares rose by 1.7%, while information technology stocks fell by 2.1% [1] Company Performance - Eli Lilly and Co. saw its stock jump approximately 10% after reporting fourth-quarter adjusted earnings of $7.54 per share, surpassing the consensus estimate of $6.67. The company's sales reached $19.3 billion, exceeding the consensus of $17.96 billion [2] Commodity Market - In commodity trading, oil prices increased by 0.4% to $63.46, while gold prices decreased by 0.5% to $4,909.70. Silver prices rose by 1.6% to $84.615, and copper prices fell by 3.2% to $5.8945 [3] European Market - European shares were mixed, with the eurozone's STOXX 600 gaining 0.03%, while Spain's IBEX 35 Index fell by 0.09%. London's FTSE 100 increased by 0.85%, Germany's DAX slipped by 0.72%, and France's CAC 40 gained 1.01% [4] Asian Market - Asian markets closed higher, with Japan's Nikkei surging by 0.78%, Hong Kong's Hang Seng Index gaining 0.05%, China's Shanghai Composite rising by 0.85%, and India's BSE Sensex increasing by 0.09% [5] Economic Indicators - The ISM Services PMI remained unchanged at 53.8 in January, matching the revised reading from December and exceeding market estimates of 53.5. The S&P Global composite PMI rose to 53.0 in January from a preliminary level of 52.8 and up from December's reading of 52.7 [7] - U.S. crude stocks declined by 3.455 million barrels for the week ending January 30, compared to market estimates of a 2 million-barrel draw [7]

U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 200 points on Wednesday.Following the market opening Wednesday, the Dow traded up 0.44% to 49,459.82 while the NASDAQ dipped 0.74% to 23,082.23. The S&P 500 also fell, dropping, 0.16% to 6,906.91.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsMaterials shares gained by 1.9% on Wednesday.In trading on Wednesday, communication services stocks fell by 1%.Top Headli ...

Core Insights - Adial Pharmaceuticals, Inc. has welcomed the recent passage of the 2026 Appropriations Bill, which includes directives for the FDA and NIDA to establish alternative clinical trial endpoints for substance use disorder treatments, including Alcohol Use Disorder (AUD) [1][2][5] Group 1: Legislative Impact - The legislation directs the FDA to consider non-abstinence-based endpoints such as reduced cravings and disorder severity, reflecting clinically meaningful improvements for patients [2][3] - This directive aligns with the NIAAA's updated definition of recovery, which emphasizes improvements in functioning and symptom reduction as valid treatment goals [3] Group 2: Company Strategy and Product Development - Adial's lead investigational therapy, AD04, is designed to treat AUD using a precision medicine approach, aligning with the newly established non-abstinence recovery outcomes [4][5] - The collaboration between federal agencies to define alternative endpoints is expected to strengthen the regulatory framework for innovative therapies like AD04, potentially accelerating development timelines and broadening clinical relevance [4][5] Group 3: Market Context - AUD remains a significant public health challenge, affecting millions with limited treatment options that achieve durable outcomes [5] - Adial believes that regulatory clarity around alternative endpoints will enhance the regulatory path for AD04 and support the company's strategy to address the unmet need in AUD with precision-based therapies [5][6]

Shares of Super Micro Computer Inc (NASDAQ:SMCI) rose sharply in pre-market trading after the company posted better-than-expected results for its second quarter.Super Micro Computer reported quarterly earnings of 69 cents per share, which beat the analyst consensus estimate of 49 cents by 41.68%, according to data from Benzinga Pro. Quarterly revenue came in at $12.68 billion, which beat the Street estimate of $10.22 billion and was up from $5.68 billion in the same period last year.Super Micro said it expe ...

GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will effect a 1-for-25 reverse stock split (the “Reverse Split”) of its common stock, par value $0.001 per share (“Common Stock”), that will become effective on February 5, 2026 at 11:59 p.m. Eastern Time (the “Effective T ...

GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will effect a 1-for-25 reverse stock split (the "Reverse Split") of its common stock, par value $0.001 per share ("Common Stock"), that will become effective on February 5, 2026 at 11:59 p.m. Eastern Time (the "Effective Ti ...

Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will effect a 1-for-25 reverse stock split (the “Reverse Split”) of its common stock, par value $0.001 per share (“Common Stock”), that will become ...

New patent based on treatment of populations identified to be particularly responsive to ondansetron treatment after examination of Adial’s clinical data and informationGLEN ALLEN, Va., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of the international patent application for AD04, f ...

Core Viewpoint - Adial Pharmaceuticals has entered into a warrant inducement agreement with an institutional investor for the immediate exercise of existing warrants, aiming to raise approximately $2.86 million for working capital and corporate purposes [1][3]. Group 1: Warrant Inducement Agreement - The agreement involves the immediate exercise of Series C-1 Warrants to purchase up to 4,025,000 shares and Series E Warrants to purchase up to 5,190,675 shares at a reduced exercise price of $0.31 [1]. - The investor will receive new unregistered Series F Warrants to purchase up to 13,823,512 shares, with the same exercise price of $0.31, which will be exercisable upon shareholder approval [3]. - The closing of this transaction is expected around December 1, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and other general corporate purposes [1]. Group 3: Company Overview - Adial Pharmaceuticals is focused on developing therapies for addiction and related disorders, with its lead product AD04 targeting Alcohol Use Disorder (AUD) [6]. - AD04 has shown promising results in reducing heavy drinking in patients during the ONWARD™ pivotal Phase 3 clinical trial, with no significant safety concerns reported [6]. - The company believes AD04 may also have potential applications for treating other addictive disorders such as Opioid Use Disorder, gambling, and obesity [6].